The Cancer Letter

Inside information on cancer research and drug development

In Brief

St. Jude Children’s Research Hospital opens Marlo Thomas Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ST. JUDE CHILDREN’S RESEARCH HOSPITAL dedicated and opened The Marlo Thomas Center for Global Education & Collaboration on the St. Jude campus in Memphis, Tenn., Nov. 20. The center will focus on childhood cancer.

The center will also become the hub for the St. Jude International Outreach Program, which has 25 official partner sites in 17 countries. The center also will support the training of St. Jude’s postdoctoral and graduate fellows.

The center is named for St. Jude National Outreach Director Marlo Thomas. Both she and Hillary Clinton were scheduled to attend the dedication, with Clinton as honored guest and featured speaker. Clinton also attended the 1994 dedication of the St. Jude Patient Care Center when she served as first lady.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account